Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Stryker Corporation — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $29.12 (market cap $6.76B), while Stryker Corporation trades at $282 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 16× Janus Living Inc. Class A-1 Common Stock's market cap, and Janus Living Inc. Class A-1 Common Stock pays the higher dividend (1.98%). Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| JAN | SYK | |
|---|---|---|
Market Cap | $6.76B | $108.38B |
Volume | 1,332,082 | 2,068,363 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $388.35 |
52-Week Low | $22.88 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $6.85B | $119.84B |
Dividend Yield | 1.98% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
